Results 11 to 20 of about 5,262,545 (393)

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

Journal of the American College of Cardiology, 2020
Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability.
Gregory A. Roth, G. Mensah, C. Johnson, G. Addolorato, E. Ammirati, L. Baddour, N. Barengo, A. Beaton, E. Benjamin, Catherine P. Benziger, A. Bonny, Michael Brauer, M. Brodmann, T. Cahill, J. Carapetis, A. Catapano, S. Chugh, Leslie T. Cooper, J. Coresh, M. Criqui, N. Decleene, K. Eagle, Sophia Emmons-Bell, V. Feigin, J. Fernandez-Solà, G. Fowkes, E. Gakidou, S. Grundy, F. He, G. Howard, F. Hu, L. Inker, G. Karthikeyan, N. Kassebaum, W. Koroshetz, C. Lavie, D. Lloyd-Jones, Hongmin Lu, A. Mirijello, A. M. Temesgen, A. Mokdad, A. Moran, P. Muntner, J. Narula, Bruce Neal, M. Ntsekhe, G. M. Moraes de Oliveira, C. Otto, M. Owolabi, M. Pratt, S. Rajagopalan, M. Reitsma, A. Ribeiro, N. Rigotti, A. Rodgers, C. Sable, Saate S. Shakil, K. Sliwa-Hahnle, Benjamin A. Stark, J. Sundström, P. Timpel, I. Tleyjeh, M. Valgimigli, T. Vos, P. Whelton, Magdi H. Yacoub, L. Zuhlke, C. Murray, V. Fuster   +68 more
semanticscholar   +1 more source

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

New England Journal of Medicine, 2023
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in
A. M. Lincoff, Kirstine Brown-Frandsen, H. Colhoun, J. Deanfield, S. Emerson, Sille Esbjerg, S. Hardt-Lindberg, G. Hovingh, S. Kahn, Robert F. Kushner, I. Lingvay, Tugce K Oral, Marie M Michelsen, Jorge Plutzky, C. W. Tornøe, D. Ryan   +15 more
semanticscholar   +1 more source

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Circulation, 2021
The global obesity epidemic is well established, with increases in obesity prevalence for most countries since the 1980s. Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and ...
Tiffany Powell-wiley, P. Poirier, L. Burke, J. Despres, P. Gordon-Larsen, C. Lavie, S. Lear, C. Ndumele, I. Neeland, P. Sanders, M. St-Onge   +10 more
semanticscholar   +1 more source

Cardiovascular Disease [PDF]

BMC Women's Health, 2004
HEALTH ISSUE: Cardiovascular disease (CVD) is the leading cause of death in Canadian women and men. In general, women present with a wider range of symptoms, are more likely to delay seeking medial care and are less likely to be investigated and treated with evidence-based medications, angioplasty or coronary artery bypass graft than men. KEY FINDINGS:
Grace, Sherry L, Fry, Rick, Cheung, Angela, Stewart, Donna E   +3 more
openaire   +4 more sources

Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association

Circulation, 2022
In 2010, the American Heart Association defined a novel construct of cardiovascular health to promote a paradigm shift from a focus solely on disease treatment to one inclusive of positive health promotion and preservation across the life course in ...
D. Lloyd‐Jones, N. Allen, C. Anderson, Terrie Black, LaPrincess C. Brewer, R. Foraker, M. Grandner, H. Lavretsky, A. Perak, Garima V Sharma, W. Rosamond   +10 more
semanticscholar   +1 more source

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

JAMA cardiology, 2020
This case series study evaluates the association of underlying cardiovascular disease and myocardial injury on fatal outcomes in patients with coronavirus disease 2019 (COVID-19).
T. Guo, YongZhen Fan, Ming Chen, Xiaoyan Wu, Lin Zhang, T. He, Hairong Wang, J. Wan, Xinghuan Wang, Zhibing Lu   +9 more
semanticscholar   +1 more source

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Toda Kato, A. Cahn, Michael G. Silverman, Thomas A. Zelniker, J. Kuder, S. Murphy, Deepak L. Bhatt, Lawrence A Leiter, Darren K Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine   +19 more
semanticscholar   +1 more source

Long-term cardiovascular outcomes of COVID-19

Nature Medicine, 2022
The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized.
Yan Xie, Evan Xu, Benjamin Bowe, Z. Al-Aly   +3 more
semanticscholar   +1 more source

Cardiovascular pharmacogenomics

Experimental Physiology, 2005
There is large interpatient variability in the response to drugs, including cardiovascular drugs. Thus, while some patients achieve the desired therapeutic response from their drug therapy, others do not. There is also a subset of patients who will experience adverse effects, which can range from bothersome to life threatening. Research in recent years
Julie A, Johnson, Larisa H, Cavallari
openaire   +2 more sources

COVID-19 and the cardiovascular system

Nature Reviews Cardiology, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular ...
Ying-Ying Zheng, Yi-tong Ma, Jin-Ying Zhang, Xiang Xie   +3 more
semanticscholar   +1 more source